Six European hospitals led by Puerta de Hierro participate
Six European hospitals led by Puerta de Hierro participate
The antibody manages to remove the amyloid protein already deposited and opens the door to new drugs for the increasingly frequent cardiac amyloidosis due to transthyretin.
On the left, amyloid plaques in the heart of a patient. On the right, the same patient with less amyloid one year following taking the drug. Signature: Puerta de Hierro University Hospital-CNIC.
Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
